Skip to main content
. 2018 Jul 27;2(4):e136. doi: 10.1097/HS9.0000000000000136

Table 3.

Summary of Findings: Rituximab Maintenance Compared to Observation or Interferon for Patients With Mantle Cell Lymphoma

graphic file with name hs9-2-e136-g005.jpg